{"id":"https://openalex.org/W2031998778","doi":"https://doi.org/10.1016/j.ejca.2008.12.012","title":"Different antiproliferative effects of matuzumab and cetuximab in A431 cells are associated with persistent activity of the MAPK pathway","display_name":"Different antiproliferative effects of matuzumab and cetuximab in A431 cells are associated with persistent activity of the MAPK pathway","publication_year":2009,"publication_date":"2009-01-22","ids":{"openalex":"https://openalex.org/W2031998778","doi":"https://doi.org/10.1016/j.ejca.2008.12.012","mag":"2031998778","pmid":"https://pubmed.ncbi.nlm.nih.gov/19167213"},"language":"en","primary_location":{"id":"doi:10.1016/j.ejca.2008.12.012","doi":"https://doi.org/10.1016/j.ejca.2008.12.012","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.ejca.2008.12.012","pdf_url":null,"source":{"id":"https://openalex.org/S16731738","display_name":"European Journal of Cancer","issn_l":"0959-8049","issn":["0959-8049","1879-0852"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Cancer","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5033621761","display_name":"D\u00e9bora Dummer Meira","orcid":"https://orcid.org/0000-0002-6092-2459","observed_orcids":["https://orcid.org/0000-0002-6092-2459"]},"institutions":[{"id":"https://openalex.org/I40034438","display_name":"Universidade do Estado do Rio de Janeiro","ror":"https://ror.org/0198v2949","country_code":"BR","type":"education","lineage":["https://openalex.org/I40034438"]},{"id":"https://openalex.org/I4210142683","display_name":"Instituto Nacional de C\u00e2ncer - INCA","ror":"https://ror.org/055n68305","country_code":"BR","type":"healthcare","lineage":["https://openalex.org/I4210142683"]}],"countries":["BR"],"is_corresponding":false,"raw_author_name":"Debora Dummer Meira","raw_affiliation_strings":["Division of Clinical Research, Instituto Nacional de C\u00e2ncer (INCA), Rua Andr\u00e9 Cavalcanti, No. 37, 2\u00b0 andar, Centro, Rio de Janeiro, Cep: 20231-050, RJ, Brazil; Departamento de Bioqu\u00edmica, IBRAG, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil","Departamento de Bioqu\u00edmica, IBRAG, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil","Division of Clinical Research, Instituto Nacional de C\u00e2ncer (INCA), Rua Andr\u00e9 Cavalcanti, No. 37, 2\u00b0 andar, Centro, Rio de Janeiro, Cep: 20231-050, RJ, Brazil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Clinical Research, Instituto Nacional de C\u00e2ncer (INCA), Rua Andr\u00e9 Cavalcanti, No. 37, 2\u00b0 andar, Centro, Rio de Janeiro, Cep: 20231-050, RJ, Brazil; Departamento de Bioqu\u00edmica, IBRAG, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil","institution_ids":["https://openalex.org/I40034438","https://openalex.org/I4210142683"]},{"raw_affiliation_string":"Departamento de Bioqu\u00edmica, IBRAG, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil","institution_ids":["https://openalex.org/I40034438"]},{"raw_affiliation_string":"Division of Clinical Research, Instituto Nacional de C\u00e2ncer (INCA), Rua Andr\u00e9 Cavalcanti, No. 37, 2\u00b0 andar, Centro, Rio de Janeiro, Cep: 20231-050, RJ, Brazil","institution_ids":["https://openalex.org/I4210142683"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111703675","display_name":"Isabel P N\u00f3brega","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210142683","display_name":"Instituto Nacional de C\u00e2ncer - INCA","ror":"https://ror.org/055n68305","country_code":"BR","type":"healthcare","lineage":["https://openalex.org/I4210142683"]}],"countries":["BR"],"is_corresponding":false,"raw_author_name":"Isabel N\u00f3brega","raw_affiliation_strings":["Division of Clinical Research, Instituto Nacional de C\u00e2ncer (INCA), Rua Andr\u00e9 Cavalcanti, No. 37, 2\u00b0 andar, Centro, Rio de Janeiro, Cep: 20231-050, RJ, Brazil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Clinical Research, Instituto Nacional de C\u00e2ncer (INCA), Rua Andr\u00e9 Cavalcanti, No. 37, 2\u00b0 andar, Centro, Rio de Janeiro, Cep: 20231-050, RJ, Brazil","institution_ids":["https://openalex.org/I4210142683"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011160312","display_name":"Vitor Hugo de Almeida","orcid":"https://orcid.org/0000-0002-2789-7116","observed_orcids":["https://orcid.org/0000-0002-2789-7116"]},"institutions":[{"id":"https://openalex.org/I4210142683","display_name":"Instituto Nacional de C\u00e2ncer - INCA","ror":"https://ror.org/055n68305","country_code":"BR","type":"healthcare","lineage":["https://openalex.org/I4210142683"]}],"countries":["BR"],"is_corresponding":false,"raw_author_name":"Vitor Hugo de Almeida","raw_affiliation_strings":["Division of Clinical Research, Instituto Nacional de C\u00e2ncer (INCA), Rua Andr\u00e9 Cavalcanti, No. 37, 2\u00b0 andar, Centro, Rio de Janeiro, Cep: 20231-050, RJ, Brazil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Clinical Research, Instituto Nacional de C\u00e2ncer (INCA), Rua Andr\u00e9 Cavalcanti, No. 37, 2\u00b0 andar, Centro, Rio de Janeiro, Cep: 20231-050, RJ, Brazil","institution_ids":["https://openalex.org/I4210142683"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009252938","display_name":"J\u00e2nio da Silva Moror\u00f3","orcid":"https://orcid.org/0000-0001-5885-7726","observed_orcids":["https://orcid.org/0000-0001-5885-7726"]},"institutions":[{"id":"https://openalex.org/I4210142683","display_name":"Instituto Nacional de C\u00e2ncer - INCA","ror":"https://ror.org/055n68305","country_code":"BR","type":"healthcare","lineage":["https://openalex.org/I4210142683"]}],"countries":["BR"],"is_corresponding":false,"raw_author_name":"J\u00e2nio S. Moror\u00f3","raw_affiliation_strings":["Division of Clinical Research, Instituto Nacional de C\u00e2ncer (INCA), Rua Andr\u00e9 Cavalcanti, No. 37, 2\u00b0 andar, Centro, Rio de Janeiro, Cep: 20231-050, RJ, Brazil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Clinical Research, Instituto Nacional de C\u00e2ncer (INCA), Rua Andr\u00e9 Cavalcanti, No. 37, 2\u00b0 andar, Centro, Rio de Janeiro, Cep: 20231-050, RJ, Brazil","institution_ids":["https://openalex.org/I4210142683"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019342774","display_name":"Alexander Machado Cardoso","orcid":"https://orcid.org/0000-0003-2974-0232","observed_orcids":["https://orcid.org/0000-0003-2974-0232"]},"institutions":[{"id":"https://openalex.org/I122140584","display_name":"Universidade Federal do Rio de Janeiro","ror":"https://ror.org/03490as77","country_code":"BR","type":"education","lineage":["https://openalex.org/I122140584"]}],"countries":["BR"],"is_corresponding":false,"raw_author_name":"Alexander M. Cardoso","raw_affiliation_strings":["Instituto de Bioqu\u00edmica M\u00e9dica, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Instituto de Bioqu\u00edmica M\u00e9dica, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil","institution_ids":["https://openalex.org/I122140584"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085284664","display_name":"Ricardo L.A. Silva","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210142683","display_name":"Instituto Nacional de C\u00e2ncer - INCA","ror":"https://ror.org/055n68305","country_code":"BR","type":"healthcare","lineage":["https://openalex.org/I4210142683"]}],"countries":["BR"],"is_corresponding":false,"raw_author_name":"Ricardo L.A. Silva","raw_affiliation_strings":["Division of Clinical Research, Instituto Nacional de C\u00e2ncer (INCA), Rua Andr\u00e9 Cavalcanti, No. 37, 2\u00b0 andar, Centro, Rio de Janeiro, Cep: 20231-050, RJ, Brazil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Clinical Research, Instituto Nacional de C\u00e2ncer (INCA), Rua Andr\u00e9 Cavalcanti, No. 37, 2\u00b0 andar, Centro, Rio de Janeiro, Cep: 20231-050, RJ, Brazil","institution_ids":["https://openalex.org/I4210142683"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039530981","display_name":"Rodolpho Mattos Albano","orcid":"https://orcid.org/0000-0002-0643-901X","observed_orcids":["https://orcid.org/0000-0002-0643-901X"]},"institutions":[{"id":"https://openalex.org/I40034438","display_name":"Universidade do Estado do Rio de Janeiro","ror":"https://ror.org/0198v2949","country_code":"BR","type":"education","lineage":["https://openalex.org/I40034438"]}],"countries":["BR"],"is_corresponding":false,"raw_author_name":"Rodolpho M. Albano","raw_affiliation_strings":["Departamento de Bioqu\u00edmica, IBRAG, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departamento de Bioqu\u00edmica, IBRAG, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil","institution_ids":["https://openalex.org/I40034438"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5087199549","display_name":"Carlos Gil Ferreira","orcid":"https://orcid.org/0000-0002-7228-7018","observed_orcids":["https://orcid.org/0000-0002-7228-7018"]},"institutions":[{"id":"https://openalex.org/I4210142683","display_name":"Instituto Nacional de C\u00e2ncer - INCA","ror":"https://ror.org/055n68305","country_code":"BR","type":"healthcare","lineage":["https://openalex.org/I4210142683"]}],"countries":["BR"],"is_corresponding":true,"raw_author_name":"Carlos Gil Ferreira","raw_affiliation_strings":["Division of Clinical Research, Instituto Nacional de C\u00e2ncer (INCA), Rua Andr\u00e9 Cavalcanti, No. 37, 2\u00b0 andar, Centro, Rio de Janeiro, Cep: 20231-050, RJ, Brazil. Electronic address: cferreira@inca.gov.br","Division of Clinical Research, Instituto Nacional de C\u00e2ncer (INCA), Rua Andr\u00e9 Cavalcanti, No. 37, 2\u00b0 andar, Centro, Rio de Janeiro, Cep: 20231-050, RJ, Brazil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Clinical Research, Instituto Nacional de C\u00e2ncer (INCA), Rua Andr\u00e9 Cavalcanti, No. 37, 2\u00b0 andar, Centro, Rio de Janeiro, Cep: 20231-050, RJ, Brazil. Electronic address: cferreira@inca.gov.br","institution_ids":["https://openalex.org/I4210142683"]},{"raw_affiliation_string":"Division of Clinical Research, Instituto Nacional de C\u00e2ncer (INCA), Rua Andr\u00e9 Cavalcanti, No. 37, 2\u00b0 andar, Centro, Rio de Janeiro, Cep: 20231-050, RJ, Brazil","institution_ids":["https://openalex.org/I4210142683"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5087199549"],"corresponding_institution_ids":["https://openalex.org/I4210142683"],"apc_list":{"value":4270,"currency":"USD","value_usd":4270},"apc_paid":null,"fwci":3.4772,"has_fulltext":false,"cited_by_count":45,"citation_normalized_percentile":{"value":0.92793009,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"45","issue":"7","first_page":"1265","last_page":"1273"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/matuzumab","display_name":"matuzumab","score":0.996999979019165},{"id":"https://openalex.org/keywords/cetuximab","display_name":"cetuximab","score":0.9879999756813049},{"id":"https://openalex.org/keywords/epidermal-growth-factor-receptor","display_name":"epidermal growth factor receptor","score":0.7979999780654907},{"id":"https://openalex.org/keywords/a431-cells","display_name":"A431 cells","score":0.8970000147819519},{"id":"https://openalex.org/keywords/mapk-signaling","display_name":"MAPK signaling","score":0.7089999914169312},{"id":"https://openalex.org/keywords/erk1-2-phosphorylation","display_name":"ERK1/2 phosphorylation","score":0.9879999756813049},{"id":"https://openalex.org/keywords/akt-phosphorylation","display_name":"Akt phosphorylation","score":0.9980000257492065},{"id":"https://openalex.org/keywords/her2","display_name":"HER2","score":0.859000027179718},{"id":"https://openalex.org/keywords/cell-cycle-arrest","display_name":"cell cycle arrest","score":0.6890000104904175},{"id":"https://openalex.org/keywords/cell-proliferation","display_name":"cell proliferation","score":0.4959999918937683},{"id":"https://openalex.org/keywords/antibody-synergy","display_name":"antibody synergy","score":0.7630000114440918},{"id":"https://openalex.org/keywords/antibody-dependent-cellular-cytotoxicity","display_name":"antibody-dependent cellular cytotoxicity","score":0.7599999904632568},{"id":"https://openalex.org/keywords/vegf-inhibition","display_name":"VEGF inhibition","score":0.8659999966621399},{"id":"https://openalex.org/keywords/egfr-downregulation","display_name":"EGFR downregulation","score":0.902999997138977},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.7799999713897705}],"concepts":[{"id":"https://openalex.org/C2779998722","wikidata":"https://www.wikidata.org/wiki/Q420296","display_name":"Cetuximab","level":4,"score":0.9505695104598999},{"id":"https://openalex.org/C47170353","wikidata":"https://www.wikidata.org/wiki/Q4649310","display_name":"A431 cells","level":5,"score":0.7271009087562561},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.6851024031639099},{"id":"https://openalex.org/C57074206","wikidata":"https://www.wikidata.org/wiki/Q14197552","display_name":"MAPK/ERK pathway","level":3,"score":0.6816326379776001},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.5840522646903992},{"id":"https://openalex.org/C75217442","wikidata":"https://www.wikidata.org/wiki/Q423650","display_name":"Protein kinase B","level":3,"score":0.5827811360359192},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5638071894645691},{"id":"https://openalex.org/C40677261","wikidata":"https://www.wikidata.org/wiki/Q21418091","display_name":"Antibody-dependent cell-mediated cytotoxicity","level":4,"score":0.5534347891807556},{"id":"https://openalex.org/C2776362946","wikidata":"https://www.wikidata.org/wiki/Q424374","display_name":"Epidermal growth factor","level":3,"score":0.51543128490448},{"id":"https://openalex.org/C11960822","wikidata":"https://www.wikidata.org/wiki/Q242736","display_name":"Phosphorylation","level":2,"score":0.5038163065910339},{"id":"https://openalex.org/C62112901","wikidata":"https://www.wikidata.org/wiki/Q189159","display_name":"Cell growth","level":2,"score":0.478208065032959},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.47131094336509705},{"id":"https://openalex.org/C2777506169","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"EGFR inhibitors","level":4,"score":0.4296516180038452},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4073895812034607},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.3586564064025879},{"id":"https://openalex.org/C29537977","wikidata":"https://www.wikidata.org/wiki/Q188941","display_name":"Cell cycle","level":3,"score":0.3221801817417145},{"id":"https://openalex.org/C1491633281","wikidata":"https://www.wikidata.org/wiki/Q7868","display_name":"Cell","level":2,"score":0.31215909123420715},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.2769891619682312},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.2310943901538849},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.22022727131843567},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.20418503880500793},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.08877131342887878},{"id":"https://openalex.org/C67082663","wikidata":"https://www.wikidata.org/wiki/Q3523816","display_name":"Molecular medicine","level":4,"score":0.0},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000068818","descriptor_name":"Cetuximab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D004357","descriptor_name":"Drug Synergism","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D005419","descriptor_name":"Flavonoids","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010766","descriptor_name":"Phosphorylation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011485","descriptor_name":"Protein Binding","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015153","descriptor_name":"Blotting, Western","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015536","descriptor_name":"Down-Regulation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020935","descriptor_name":"MAP Kinase Signaling System","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D042461","descriptor_name":"Vascular Endothelial Growth Factor A","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D049109","descriptor_name":"Cell Proliferation","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1016/j.ejca.2008.12.012","doi":"https://doi.org/10.1016/j.ejca.2008.12.012","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.ejca.2008.12.012","pdf_url":null,"source":{"id":"https://openalex.org/S16731738","display_name":"European Journal of Cancer","issn_l":"0959-8049","issn":["0959-8049","1879-0852"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Cancer","raw_type":"journal-article"},{"id":"pmid:19167213","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19167213","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European journal of cancer (Oxford, England : 1990)","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320322025","display_name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","ror":"https://ror.org/03swz6y49"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":31,"referenced_works":["https://openalex.org/W1602814083","https://openalex.org/W1804903119","https://openalex.org/W1964321121","https://openalex.org/W1967726440","https://openalex.org/W1968961303","https://openalex.org/W1972161092","https://openalex.org/W1978068596","https://openalex.org/W1992183189","https://openalex.org/W1995242599","https://openalex.org/W2003680979","https://openalex.org/W2023977540","https://openalex.org/W2039964383","https://openalex.org/W2044565900","https://openalex.org/W2068125497","https://openalex.org/W2079247990","https://openalex.org/W2091249065","https://openalex.org/W2107277218","https://openalex.org/W2112964045","https://openalex.org/W2115199224","https://openalex.org/W2116062997","https://openalex.org/W2135938911","https://openalex.org/W2139333680","https://openalex.org/W2142391389","https://openalex.org/W2150079073","https://openalex.org/W2152452482","https://openalex.org/W2155305458","https://openalex.org/W2163252214","https://openalex.org/W2168479321","https://openalex.org/W2405564704","https://openalex.org/W6680756961","https://openalex.org/W6681167329"],"related_works":["https://openalex.org/W2023977540","https://openalex.org/W7097612040","https://openalex.org/W2120034671","https://openalex.org/W2323360249","https://openalex.org/W2064022140","https://openalex.org/W1974155202","https://openalex.org/W2007199169","https://openalex.org/W2129432386","https://openalex.org/W2137600224","https://openalex.org/W2268976341"],"abstract_inverted_index":null,"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":4},{"year":2015,"cited_by_count":2},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":4}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2016-06-24T00:00:00"}